Wexford Capital’s Guardant Health GH Stock Holding History

Wexford Capital’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,739	Closed	-$330K	–	275
2025 Q1	$330K	Hold	7,739	–	–	0.09%	151
2024 Q4	$236K	Sell	7,739 -2,342	-23%	-$65.9K	0.04%	153
2024 Q3	$231K	Buy	10,081 +1,158	+13%	+$32.8K	0.06%	146
2024 Q2	$258K	Buy	+8,923	New	+$208K	0.07%	168

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Wexford Capital's GH Position: Q2 2025 in Review

Wexford Capital sold out of Guardant Health (GH) in Q2 2025, closing a stake of 7,739 shares — an estimated $330K sold.

Wexford Capital first reported a position in GH in Q2 2024 and held it in 4 quarters. The position peaked at $330K in Q1 2025. 365 funds tracked by Wall St. Rank hold GH as of Q2 2025.

Wexford Capital reported no remaining Guardant Health position as of Q2 2025 after selling out during the quarter.
Wexford Capital sold 7,739 Guardant Health shares in Q2 2025, an estimated $330K.
Wexford Capital first reported a position in Guardant Health in Q2 2024 and held it in 4 quarters.
Wexford Capital's Guardant Health position peaked at $330K in Q1 2025.
365 funds tracked by Wall St. Rank held Guardant Health as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.